Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Beyond Pills: Designing a Winning Delivery Strategy for the New Era of Biologics

By Drug Discovery Trends Editor | July 31, 2015

With the rise of biologics, drug delivery presents new challenges as many companies are still taking a fragmented approach, resulting in delayed (or suboptimal) product launches and life cycle management. The problem is that it’s extremely difficult, if not impossible, to fix drug delivery challenges after the fact, so companies need a clear strategy in advance.

Drug delivery may not sound sexy, but at least three factors – increased competition from biosimilars, formulation challenges of therapies in the pipeline, and an expansion of both disease areas and patients served by biologics – have come together to make it a critical issue for drug companies.

The Rise and Spread of Monoclonal Antibodies

Proteins like monoclonal antibodies (mAbs) are a rapidly growing segment of medicine, but they are too large to be administered orally, and require alternate delivery methods.

Many of these drugs in the pipeline have technical difficulties that will require new thinking on drug delivery. We believe that 15 to 20 percent of all proteins in development today have some kind of formulation challenge. As a result, drug companies must think about delivery early in the R&D process – even as early as molecular engineering – or they could wind up with a drug that receives FDA approval, yet isn’t commercially optimal. Moreover, as biopharma attempts to target new tissues with proteins in new ways (e.g., local targeting of the lung), formulation investments will need to be made early in the development cycle.

The Benefits of Novel Therapies

Biopharmaceutical companies that introduce a well-thought-out drug-delivery strategy should gain on multiple fronts with more patients, higher probability of hitting intended targets, better adherence to prescribed treatment regimens, and lower costs (see Figure).

The increasing move toward self-administered therapies will heighten the importance of patient acceptance, adherence and compliance. Innovative designs could be as simple as offering an injectable drug in a premixed or preloaded syringe, or creating a formulation that requires less frequent injections.

With legislation looming to promote biosimilars and increased pressure from both payers and patients to offer an increased value proposition, we believe innovation in drug delivery will become an increasingly important competitive differentiator. That occurred long ago with insulin, where there’s little therapeutic reason to choose one version of insulin over another, and devices have become a significant basis for competition. We believe something similar — if perhaps less extreme — is likely to evolve in areas where brands and biosimilars are proliferating.

A Drug Delivery Strategy

An L.E.K. survey of some 20 top global biopharmas put patient acceptance and persistence as the number one challenge that could be addressed by engaging customers with drug delivery technologies. But while these top executives realized they needed a drug-delivery strategy, few knew what to do to create one.

Here are some factors to consider:

Is a drug delivery strategy important to your organization? If you can answer yes to any of these questions, it is:     

  1. Do you have self-administered biologics in highly-competitive markets?
  2. Do you have products used by patients with special requirements such as the elderly, frail, or children?
  3. Do you have biologics in your pipeline that have formulation challenges, such as lyophilization, concentration, shearing, or coagulation? 

Will a one-off approach suffice or do you need a platform? The issue here is upfront cost vs. overall payoff.

Which technologies matter for the drugs in your pipeline? How do you ensure the strategy optimizes the needs across the portfolio?

Getting drug delivery right is crucial, but it won’t be easy. Those that can move to the forefront of new drug-delivery technologies with advanced formulations (such as nanoparticles and microspheres) or advanced devices (like microneedles and microinfusers) will be the ones that will win.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE